The Trump administration said on Wednesday it will consider “opportunities to bring greater transparency” to the ...
Zentalis Pharmaceuticals is axing about 40% of its staff and doubling down on advancing its only pipeline candidate as part ...
A Delaware judge issued a split ruling in a bizarre legal squabble over the IPO plans of Aurion Biotech, which should allow ...
Eli Lilly is discontinuing a Phase 2 relaxin treatment candidate for heart failure and chronic kidney disease, a spokesperson for the company confirmed to Endpoints News.
President Donald Trump’s communications and travel freeze at HHS may be part of the reason an upcoming FDA advisory committee ...
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu is now approved to treat a new subset of breast cancer ...
FDA expands Ozempic label to include kidney disease benefits in type 2 diabetes patients. Novo Nordisk's drug can now be ...
Novo Nordisk is asking a federal appeals court to make haste on its case challenging the Inflation Reduction Act's drug ...
Compounding facility ProRx Pharmacy Network has received an FDA warning letter over issues with its semaglutide and ...
KFF analysis highlights that ACA marketplace insurers denied 19% of claims. Less than 1% of denials were appealed, and ...
Leap Therapeutics reported mixed results on Tuesday for an experimental treatment in gastric and colorectal cancer, announcing it is only moving forward with the latter indication. The biotech’s ...
Robert F. Kennedy Jr. will sit before a Senate committee on Wednesday and provide the first substantive glimpse into how he ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback